Cortechs.ai’ imaging solutions are an important feature of Human Longevity Inc.’s new Health Nucleus.
(San Diego, CA) October 20, 2015 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce that their innovative product, NeuroQuant® is being deployed in Human Longevity Inc.’s (HLI) Health Nucleus. The HLI Health Nucleus is the first of its kind, genomic enhanced, research based health platform. The first Health Nucleus located at HLI’s San Diego Headquarters was launched October 13, 2015. Cortechs.ai and HLI began working together in May 2014 under a collaborative agreement.
HLI is building a comprehensive genomic and phenotype database, a key component in their goal of better understanding and intervening in diseases associated with human biological decline. Cortechs.ai and HLI are working together to integrate NeuroQuant and other Cortechs.ai imaging solutions with the full range of health metrics that individuals receive at HLI’s Health Nucleus. Cortechs.ai produces FDA cleared products for measuring brain atrophy in neurodegenerative diseases such as Alzheimer’s disease, epilepsy, multiple sclerosis and brain trauma and has installations at over 500 clinical radiology sites worldwide. The goal of this project is to provide the most complete description of health ever assembled, including genome and microbiome sequencing, along with metabolomics and proteomics.
Guri Stark, Cortechs.ai’ CEO remarked, “We are excited that this partnership has moved to the next phase. The HLI and Cortechs.ai collaboration affords HLI the ability to accurately and automatically measure a variety of vital phenotypes through quantitative magnetic resonance imaging and combine it with their immense experience in genomics and bioinformatics.”
“The incorporation of volumetric imaging data into our Health Nucleus, puts us one step closer to our goal of revolutionizing healthcare using the most advanced tools available for predicting, preventing, and treating disease,” said Dr. Craig Venter, Co-founder and CEO of HLI. “The image analysis tools Cortechs.ai develops and bring to market are a vital component in translating imaging data into quantifiable phenotypes.”
Cortechs.ai develops and markets cutting-edge brain imaging solutions used by neurologists and radiologists in hundreds of clinics and research centers around the world. CorTechs’ flagship product, NeuroQuant®, is a breakthrough, 510(k) cleared software medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice. As the first FDA cleared and CE marked medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant® brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician’s desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer’s disease, epilepsy, multiple sclerosis and traumatic brain injury. Please visit cortechs.ai for further information.
About Human Longevity, Inc.
Human Longevity, Inc. (HLI) is the genomics-based, technology-driven company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize the practice of medicine. A privately held company headquartered in San Diego, CA, HLI was founded in 2013 by pioneers in the fields of genomics and stem cell therapy. HLI will be licensing access to its database, and developing new diagnostics and therapeutics as part of their product offerings. For more information please visit, http://www.humanlongevity.com.
+1 858 459-9700